• Viking Therapeutics highlighted VK2735, a GLP-1/GIP dual agonist for obesity, with the VANQUISH Phase 3 registration program underway.
• The company expects Phase 3 obesity studies for oral VK2735 to begin in 4Q26.
• Oral VK2735 Phase 2a VENTURE study showed up to 12.2% mean weight loss at Week 13; placebo-adjusted weight loss reached 10.9%.
• Exploratory maintenance dosing showed continued weight loss when down-titrating from 90 mg to 30 mg through Week 13.
• Pipeline update included VK3019 in Phase 1 for obesity; VK2809 completed a successful Phase 2b VOYAGE trial in MASH.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.